TOPIC 3: TUMOR AGNOSTIC DRUG DEVELOPMENT
Medical Aspects – Irene Braña (Vall d’Hebron Institute of Oncology, ES)
Pharmaceutical Industry Aspects – Todd Riehl (Genentech, US)
Case-Study: Tumor Agnostic Approval of Larotrectinib – Chitkala Kalidas (Bayer, US)
Regulatory Aspects – Elias Pean (EMA, NL)
TOPIC 4: CELLULAR THERAPIES (INCL. CAR-T CELL THERAPIES)
Progress in Haematological Malignancies – Gerhard Ehninger (Cellex, DE)
Status in Solid Tumors – Victor Moreno Garcia (START Madrid FJD, ES)
Regulatory Aspects – Martina Schüssler-Lenz (CAT Chair, Committee for Advanced Therapies, EMA, NL)
HTA Issues – Stephen Palmer (York University, UK)